2015
A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children
Brousseau D, Scott J, Badaki-Makun O, Darbari D, Chumpitazi C, Airewele G, Ellison A, Smith-Whitley K, Mahajan P, Sarnaik S, Casper T, Cook L, Dean J, Leonard J, Hulbert M, Powell E, Liem R, Hickey R, Krishnamurti L, Hillery C, Nimmer M, Panepinto J, Network F. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood 2015, 126: 1651-1657. PMID: 26232172, PMCID: PMC4591790, DOI: 10.1182/blood-2015-05-647107.Peer-Reviewed Original ResearchConceptsSickle cell pain crisisLength of stayPediatric Emergency Care Applied Research NetworkPain crisisIntravenous magnesiumOpioid useNormal saline placeboStudy drug infusionPlacebo-controlled trialHealth-related qualityQuality of lifeMorphine equivalentsStudy drugSaline placeboSecondary outcomesStandard therapyHemoglobin SSPediatric patientsPrimary outcomeDrug infusionPain relieversPlaceboStayChildren 4Group demographics
2014
A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle‐cell disease
Creary S, Gladwin M, Byrne M, Hildesheim M, Krishnamurti L. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle‐cell disease. Pediatric Blood & Cancer 2014, 61: 1068-1073. PMID: 24436121, DOI: 10.1002/pbc.24931.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnemia, Sickle CellAntisickling AgentsCell PhoneChildChild, PreschoolDirectly Observed TherapyDrug Administration ScheduleElectronic MailFeedbackFemaleHealth SurveysHumansHydroxyureaMaleMedication AdherenceMicrocomputersPatient SatisfactionPilot ProjectsReimbursement, IncentiveReminder SystemsRewardText MessagingVideo RecordingYoung AdultConceptsSickle cell diseaseMedian medication possession ratioMean corpuscular volumeHU adherenceHydroxyurea adherencePilot studyHemoglobin F percentageMedication possession ratioParticipant satisfactionPossession ratioSecondary outcomesPediatric patientsPrimary outcomeStudy entryClinical outcomesHU useHU therapyOverall participant satisfactionSingle institutionCell diseaseReminder alertsCorpuscular volumeTherapyAdherenceOverall median